Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer

Clin Nucl Med. 2020 Sep;45(9):707-708. doi: 10.1097/RLU.0000000000003190.

Abstract

Triplet chemotherapy (FOLFOXIRI) + bevacizumab regimen is indicated as first-line treatment of BRAF-mutated metastatic colorectal cancer (mCRC). Nevertheless, its proven therapeutic efficacy in clinical trials was solely based on partial morphologic responses assessed by CT. To date, only 1 case of complete response assessed by FDG PET/CT was reported in literature in BRAF-mutated mCRC, but treated with doublet chemotherapy (FOLFIRI) + cetuximab regimen. We report a complete metabolic response assessed by FDG PET/CT, maintained over time (13 months) in a 60-year-old woman with BRAF-mutated mCRC treated by FOLFOXIRI-bevacizumab. This also confirms that FDG PET/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab / therapeutic use*
  • Camptothecin / analogs & derivatives*
  • Camptothecin / therapeutic use
  • Cetuximab / therapeutic use
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / metabolism*
  • Colorectal Neoplasms / pathology
  • Female
  • Fluorodeoxyglucose F18*
  • Fluorouracil / therapeutic use
  • Humans
  • Leucovorin / therapeutic use
  • Middle Aged
  • Mutation
  • Neoplasm Metastasis
  • Organoplatinum Compounds / therapeutic use
  • Positron Emission Tomography Computed Tomography*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Treatment Outcome

Substances

  • Organoplatinum Compounds
  • Fluorodeoxyglucose F18
  • Bevacizumab
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Cetuximab
  • Leucovorin
  • Fluorouracil
  • Camptothecin

Supplementary concepts

  • FOLFOXIRI protocol